Clinical Trial Update: A POC and Dose-Ranging Study of HTD1801 in PSC Patients [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging and proof-of-concept study of HTD1801 in Primary Sclerosing Cholangitis (PSC) has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• HTD1801

Snippet

Sponsor: HighTide Biopharma Pty Ltd | Conditions: Primary Sclerosing Cholangitis (PSC) | Phase 2 | Status: COMPLETED | Results posted: 2022-04-06